<DOC>
	<DOCNO>NCT00571649</DOCNO>
	<brief_summary>This study evaluate extend therapy oral rivaroxaban prevent blood clot leg lung occur patient hospitalize acute medical illness , compare result standard enoxaparin dose duration regimen . The safety rivaroxaban also study .</brief_summary>
	<brief_title>Venous Thromboembolic Event ( VTE ) Prophylaxis Medically Ill Patients</brief_title>
	<detailed_description>The treatment period follow follow-up period start day last intake study medication , regardless actual duration study drug administration end Day 90 ( + 7 day ) . Participants complete treatment period also enter follow-up period . It also possible participant enter follow-up period , e.g . due withdrawal consent termination study participation . Within US 'Johnson &amp; Johnson Pharmaceutical Research &amp; Development , L.L.C . ' sponsor .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Male female patient age 40 year Patients risk venous thromboembolic event hospitalize acute medical condition follow : Heart failure , New York Heart Association ( NYHA ) class III IV Active cancer Acute ischemic stroke Acute infectious inflammatory disease , include acute rheumatic disease Acute respiratory insufficiency Additional risk factor VTE , include reduce mobility Conditions contraindicate use antithrombotic therapy Low MolecularWeight Heparin ( LMWH ) enoxaparin Conditions may increase risk bleeding , include intracranial hemorrhage Required drug procedure may interfere study treatment Concomitant condition disease may increase risk study subject interfere study outcome General condition subject suitable participate study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acute medical illness increase risk VTE .</keyword>
	<keyword>Deep vein thrombosis ( DVT )</keyword>
	<keyword>Pulmonary embolism ( PE ) ,</keyword>
	<keyword>Venous Thromboembolic disease ( VTE ) ,</keyword>
	<keyword>Medical illness</keyword>
</DOC>